This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredient Nilotinib (ATC: L01EA03) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
345 days left to bid. Opened 1 years ago, deadline 30 May 2027.
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medications containing the active ingredient Timolol (ATC: S01ED01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
This publication is about entering into non-exclusive discount contracts according to § 130a Abs. 8 SGB V for finished medicines containing the active ingredient Abaloparatide (ATC: H05AA04) as part of an "open-house model". Under uniform contract conditions and a standardized access procedure, all
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Rivaroxaban (ATC: B01AF01 - in all strengths except 2.5 mg per divided oral dosage form) under an 'open-house model'. All eligible and interested ph
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredients Tramadol and Paracetamol (ATC: N02AJ13) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to ent
Adoption Counts is accepting applications for a therapy services framework that reopens every 4 months to ensure market competition and access to innovative support services.
Betsi Cadwaladr University Health Board is procuring pathology testing services for HFE gene analysis and extraction.
Powys Teaching Health Board seeks an experienced dental provider to deliver NHS General Dental Services in Llandrindod Wells.
UK Atomic Energy Authority seeks suppliers of Infrared Thermography Cameras for MAST-U diagnostic equipment; responses due 3 June 2026.
